Brief Report
Volume 12:6, 2024

Journal of Clinical & Medical Genomics

ISSN: 2472-128X Open Access

Phenotypic Impact of Heterozygous Rare Variants in LIPC, the Hepatic Lipase Gene

Dearl Cheng*

Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Introduction

The Hepatic Lipase (LIPC) gene encodes an enzyme that plays a crucial role in lipid metabolism, particularly in the hydrolysis of triglyceride-rich lipoproteins. Hepatic lipase, produced primarily in the liver, contributes to the remodeling of lipoproteins like High-Density Lipoproteins (HDL) and Low-Density Lipoproteins (LDL), which are central to cholesterol transport and metabolism. The LIPC enzyme is involved in converting Very Low-Density Lipoprotein (VLDL) to Intermediate-Density Lipoprotein (IDL) and LDL, as well as regulating the clearance of lipoproteins from circulation. Given its essential role in lipid metabolism, variants in the LIPC gene-especially rare heterozygous variants-can have significant effects on lipid profiles and may predispose individuals to various phenotypic outcomes, including altered cholesterol levels and increased cardiovascular risk. Rare genetic variants are defined as those occurring with a frequency of less than 1% in the general population. These variants can lead to different clinical consequences, depending on the gene affected, the nature of the mutation, and the environmental context. In the case of LIPC, heterozygous rare variants are often less well-studied compared to homozygous mutations, but emerging research indicates that even single-copy mutations can disrupt normal hepatic lipase function. The phenotypic effects of these variants are complex, as they may not cause immediate, severe disease but may still lead to long-term changes in lipid metabolism that affect overall health.

Description

The impact of heterozygous rare variants in LIPC on lipid metabolism is most commonly observed through changes in the concentrations and composition of lipoproteins. Hepatic lipase has a well-documented role in HDL metabolism. It is involved in hydrolyzing triglycerides from HDL particles, which allows the particles to mature and become more effective in reverse cholesterol transport-a process that facilitates the removal of excess cholesterol from peripheral tissues and the transport of it to the liver for excretion. When there are rare variants in the LIPC gene, the enzyme activity can be reduced, leading to the accumulation of less mature HDL particles with impaired functionality. This reduction in HDL cholesterol, often referred to as “good” cholesterol, is a known risk factor for cardiovascular disease, as HDL plays a protective role in preventing the buildup of plaques in the arteries. Moreover, rare LIPC variants can also have an impact on LDL metabolism. Hepatic lipase is involved in converting VLDL to LDL by hydrolyzing triglycerides in the VLDL particles.

The management of individuals with heterozygous LIPC variants typically focuses on addressing lipid imbalances and reducing cardiovascular risk factors. In cases where lipid abnormalities such as low HDL cholesterol, high triglycerides, or small, dense LDL particles are present, lifestyle interventions are often recommended. These interventions may include dietary modifications, such as increasing the intake of healthy fats (e.g., omega-3 fatty acids), reducing refined carbohydrates, and improving overall diet quality. Physical activity is also an essential component of managing lipid imbalances, as exercise can increase HDL cholesterol and improve overall lipid profiles. In more severe cases, pharmacological treatments such as statins, fibrates, or omega-3 fatty acid supplements may be prescribed to help manage cholesterol and triglyceride levels [1,2].

Conclusion

In conclusion, heterozygous rare variants in the LIPC gene have a significant impact on lipid metabolism, contributing to changes in the levels and composition of lipoproteins that increase the risk of cardiovascular disease, insulin resistance, and metabolic disorders. While these variants do not always result in overt disease, their long-term effects on lipid profiles and overall health are noteworthy. Continued research is essential to fully understand the mechanisms behind these variants and to develop effective strategies for managing the associated health risks. In the meantime, lifestyle interventions, regular monitoring, and personalized treatment plans will remain key components in managing individuals with heterozygous LIPC variants and reducing the risk of associated health complications.

References

1. Kobayashi, Junji, Kazuya Miyashita, Katsuyuki Nakajima and Hiroshi Mabuchi. "Hepatic lipase: A comprehensive view of its role on plasma lipid and lipoprotein metabolism." *J Atheroscler Thromb* 22 (2015): 1001-1011.
2. Dichek, Helén L., Sarah M. Johnson, Hassibullah Akeefe and Giai T. Lo, et al. "Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice." *J Lipid Res* 42 (2001): 201-210.

***Address for Correspondence:** Dearl Cheng, Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; E-mail: cheng.yu@gmail.com*

Received: 02 December, 2024, Manuscript No. JCMG-25-159930; **Editor assigned:** 04 December, 2024, Pre QC No. P-159930; **Reviewed:** 18 December, 2024, QC No. Q-159930; **Revised:** 24 December, 2024, Manuscript No. R-159930; **Published:** 31 December, 2024, DOI: 10.37421/2472-128X.2024.12.314

How to cite this article: Cheng, Dearl. “Phenotypic Impact of Heterozygous Rare Variants in LIPC, the Hepatic Lipase Gene.” *J Clin Med Genomics* 12 (2024): 314.